Gracell Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary

Gracell Biotechnologies

14/08/2023 16:31

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 40 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Gracell Biotechnologies Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Gracell Biotechnologies Inc shares had risen by 0.8% this
quarter and gained 67.0% so far this year.
    * The company reported a quarterly loss of $11.65 million.
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 03:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.40          -0.30          Beat
 Mar. 31 2023      -0.39          -0.35          Beat
 Dec. 31 2022      -0.21          -0.30          Missed
 Sep. 30 2022      -0.15          -0.35          Missed